Journal
LUNG CANCER
Volume 175, Issue -, Pages 17-26Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2022.11.010
Keywords
NSCLC; Patient experience; Distress; Immunotherapy
Categories
Ask authors/readers for more resources
This study provides real-world data on patient-reported outcomes in metastatic non-small cell lung cancer (mNSCLC) with immunotherapies and chemotherapy. The findings suggest that patients experience significant distress before starting treatment, and immunotherapy is associated with higher clinical response rates and lower healthcare utilization compared to chemotherapy. The study also highlights potential unmet palliative care needs in mNSCLC patients receiving immunotherapy.
Objectives: There are limited real-world data about patient-reported outcomes with immunotherapies (IO) in metastatic non-small cell lung cancer (mNSCLC). We describe patient-reported distress and clinical outcomes with IO-based treatments or cytotoxic chemotherapies (Chemo). Methods: We conducted a single-institution retrospective chart review of adults with mNSCLC treated at Duke from 03/2015 to 06/2020. At each visit, patients self-reported their distress level and sources of distress using the NCCN Distress Thermometer (DT) and its 39-item Problem List. We abstracted demographic, clinical, distress, and investigator assessed-clinical response data, then analyzed these using descriptive statistics and generalized estimating equations. Results: Data from 152 patients were analyzed in four groups: Chemo alone, IO + Chemo, single agent IO, dual agent IO. Distress was worse before treatment start in all groups, and the odds of actionable distress (DT score > 4) decreased by 10 % per month. The most frequent sources of distress were physical symptoms (e.g., fatigue, pain), which remained high longitudinally. Patients receiving IO had higher clinical response rates and a lower rate of unplanned healthcare encounters compared to patients treated with Chemo alone. Only one-third of all patients were seen by palliative care. Conclusions: This single-center, real-world evidence study demonstrates that patients with mNSCLC experience significant distress prior to starting first-line treatment. IO treatment was associated with higher clinical benefit rates and lower healthcare utilization compared to chemotherapy. Symptom distress persists over time, highlighting potential unmet palliative and supportive care needs in mNSCLC care in the IO treatment era.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available